Login to Your Account

Pharma: Clinic Roundup

Tuesday, March 6, 2012
• Teva Pharmaceuticals Ltd., of Jerusalem, reported findings from four Phase III trials showing that QNASL (beclomethasone dipropionate), a nasal aerosol corticosteroid, produced a significant change from baseline weekly averages of the subject-reported 24-hour reflective nasal symptom scores (rTNSS) over the first 30 weeks of treatment in patients with seasonal allergic rhinitis and perennial allergic rhinitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription